evipedia.ai
← Back

Quercetin for Health & Longevity

Evidence Review created on 10/30/2026 using AI4L / Opus 5.5

Also known as: 3,3′,4′,5,7-Pentahydroxyflavone, Sophoretin, Meletin, Quercetol, Quercetin Aglycone, Quercetin Dihydrate, Quercetin Phytosome, Quercefit

Motivation

Quercetin is a yellow plant pigment found in onions, capers, apples, kale and tea, and sold as an inexpensive dietary supplement. It draws interest from health-focused adults because it acts on processes tied to aging: it blocks several enzymes that cells use to pass on internal signals, and, paired with a prescription cancer drug, it is used to target worn-out cells that stop dividing but linger in tissues and feed low-grade inflammation.

Interest arrived in waves. Population studies of diets rich in such pigments first drew attention to the compound, sports scientists then tested it in athletes during heavy training, and since the mid-2010s aging researchers have studied it as one half of the first drug pair designed to clear lingering aged cells. Blood pressure, infection and the biology of aging are the areas discussed most often.

This review examines the human evidence for quercetin taken alone and in that drug pairing: which benefits are supported and how strongly, which side effects and drug interactions are documented, which doses and forms have been tested, and where the evidence is still thin, for adults pursuing a long and healthy life.

Benefits - Risks - Protocol - Conclusion

High-level overviews of quercetin’s evidence, mechanisms and use from priority experts.

  • Quercetin - FoundMyFitness

    A referenced overview of quercetin’s pharmacokinetics (absorption and clearance), exercise and immune research, and use with dasatinib to clear senescent (aged, non-dividing) cells, noting that most findings are preclinical.

  • Can Quercetin Help Heal a Leaky Gut? - Kelsey Kinney

    Explains the mast-cell (histamine-releasing immune cell) and tight-junction (seals between gut-lining cells) rationale for quercetin in gut-barrier health, mainly from rodent data; the site carries affiliate links.

  • Quercetin: Broad-Spectrum Protection - Anne Buckley

    Surveys cardiovascular, cancer, allergy and lifespan claims, largely from laboratory and animal studies; published by Life Extension, which sells quercetin supplements and so has a financial interest in favorable conclusions.

  • Personalized Medicine Approach to Senolytics Clinical Trials - Anna Drangowska-Way

    Summarizes human dasatinib-plus-quercetin trial results and the hypothesis that mainly people with a high burden of senescent cells respond, a central question for healthy adults.

  • Targeting senescent cells for cognitive health - Kathryn Birkenbach & Peter Attia

    Reviews the first dasatinib-plus-quercetin trial in Alzheimer’s disease, noting that quercetin was undetectable in cerebrospinal fluid and that a five-person unblinded pilot cannot establish brain benefit.

Andrew Huberman’s platform has no in-depth quercetin content: the only match is a brief mention by guest David Sinclair within a broader aging episode (Dr. David Sinclair: The Biology of Slowing & Reversing Aging), too brief to qualify; Rhonda Patrick’s platform is represented by its unsigned FoundMyFitness topic page.

Grokipedia

  • Quercetin

    An encyclopedic summary of quercetin’s chemistry, dietary sources, pharmacokinetics and studied uses, useful for orientation; it is AI-written, and its claims are not individually verified.

Examine

  • Quercetin benefits, dosage, and side effects

    An independent summary that grades human evidence by outcome, including blood pressure, inflammation and metabolic markers, with dosing and safety notes; Examine accepts no industry funding.

ConsumerLab

  • Quercetin & Rutin Supplements Review

    Independent testing found one rutin product with 17.4% of its labeled amount; the review also covers evidence, dosing with fatty meals and drug-interaction cautions; full results require paid membership.

Systematic Reviews

Human meta-analyses covering blood pressure, cardiometabolic markers, exercise capacity and viral infection outcomes.

No systematic review or meta-analysis of quercetin’s adverse effects or drug interactions was found on PubMed, so the principal risk side of the trade-off is unrepresented here.

Mechanism of Action

Quercetin (3,3′,4′,5,7-pentahydroxyflavone) is a flavonol (a flavonoid, one of a family of plant pigments) with overlapping actions:

  • Signaling inhibition: it inhibits PI3K (phosphoinositide 3-kinase, a cell-survival signaling enzyme) and dampens NF-κB (nuclear factor kappa B, a master switch for inflammatory genes).
  • Senolytic activity: senolytics selectively kill senescent cells (aged cells that stop dividing and secrete inflammatory factors). Quercetin cleared senescent human endothelial (blood-vessel lining) cells and dasatinib cleared senescent fat-cell precursors, so the two were paired (Zhu 2015); Mayo Clinic, where this originated, holds senolytic patents and its investigators report financial interests (Mayo Clinic news release). Another group found it not senolytic in adult human endothelial cells (Hwang 2018).
  • Enzyme targets: it inhibits xanthine oxidase (the enzyme that makes uric acid) and, in cells, CD38 (an enzyme degrading NAD+, nicotinamide adenine dinucleotide, an energy cofactor) (Escande 2013), and it stabilizes mast cells (immune cells that release histamine).
  • Antioxidant claim: test-tube radical scavenging is strong, but blood levels are low and mostly conjugated, and supplements did not change human antioxidant status (Egert 2008).
  • Pharmacology: oral bioavailability is low; gut and liver conjugate it via UGT (UDP-glucuronosyltransferase), SULT (sulfotransferase) and COMT (catechol-O-methyltransferase) enzymes, which tag molecules for excretion. Elimination half-life is about 11 hours (Graefe 2001). Selectivity is low: it modulates CYP3A4, CYP2C9, CYP2E1 and CYP1A2 (cytochrome P450 drug-metabolizing liver enzymes) and the transporters P-glycoprotein (a drug efflux pump) and OATP1B1 (organic anion-transporting polypeptide 1B1, a liver uptake transporter). It was undetectable in cerebrospinal fluid after oral dosing (Gonzales 2023).

Historical Context & Evolution

Quercetin is named after Quercus, the oak genus. Its original uses were as a natural dye and, from the 1930s, as part of the citrus “vitamin P” flavonoid complex proposed for capillary fragility (easily broken small blood vessels); the vitamin label was later abandoned because no deficiency disease could be shown.

Each later stage revised the picture:

  • Toxicology concerns: bacterial mutation assays in the 1970s raised cancer concerns. A two-year rat study found mostly benign kidney tumors in male rats at very high doses and none elsewhere (Dunnick 1992), and IARC (International Agency for Research on Cancer) rated quercetin not classifiable as a human carcinogen (IARC monograph).
  • Diet and heart disease: a Dutch cohort tied flavonol-rich diets to lower coronary death (Hertog 1993), which made purified quercetin a candidate supplement; an intravenous cancer trial then found kidney toxicity as the dose limit (Ferry 1996).
  • Exercise and immunity: in the 2000s, exercise scientists tested quercetin for endurance and upper respiratory infections after heavy training (Nieman 2007), and the FDA (US Food and Drug Administration) raised no questions about its GRAS (generally recognized as safe) status for food use in GRAS notice (GRN) 341, filed by the commercially interested supplier Quercegen Pharma (FDA GRN 341).
  • Senolytic era: the 2015 pairing with dasatinib (Zhu 2015) moved quercetin into aging research. Uncontrolled pilots looked encouraging, but an open-label bone trial missed its primary endpoint (Farr 2024), while a liver-fibrosis (liver scarring) trial reported benefit (Koning 2026), leaving its standing open.

Expected Benefits

High 🟩 🟩 🟩

Lower Blood Pressure ⚠️ Conflicted

Meta-analyses of placebo-controlled trials find small systolic and diastolic reductions, mainly at 500 mg/day or more (Serban 2016; Huang 2020). Contributing trials come from independent groups, including Edwards (730 mg/day, falls only in stage 1 hypertension; Edwards 2007) and Egert (150 mg/day; Egert 2009). A 1 g/day trial in healthy adults found no change (Conquer 1998), and an umbrella review found systolic but not diastolic benefit (Arabi 2023). Net: a modest systolic reduction, largest with elevated pressure and negligible in adults with normal blood pressure.

Magnitude: Systolic −3.04 mmHg (millimeters of mercury) (95% CI, confidence interval, the range likely to hold the true effect: −5.75 to −0.33) and diastolic −2.63 mmHg (95% CI −3.26 to −2.01) versus placebo across 7 trials (Serban 2016).

Medium 🟩 🟩

Lower Serum Uric Acid

In a crossover (each participant received both treatments in turn) RCT (randomized controlled trial) of 22 men with high-normal uric acid, 500 mg/day for 4 weeks lowered plasma uric acid without changing glucose or blood pressure (Shi 2016). The proposed mechanism is xanthine oxidase inhibition. Evidence comes from one trial by one group, in men only, and gout prevention has not been tested.

Magnitude: −26.5 µmol/L versus placebo (95% CI −7.6 to −45.5) (Shi 2016).

Less Liver Fat in Fatty Liver Disease

In a 12-week crossover RCT in 41 adults with NAFLD (nonalcoholic fatty liver disease), 500 mg/day reduced liver fat measured by MRI (magnetic resonance imaging), partly explained by greater weight loss, with a non-significant trend toward larger falls in women (Li 2024). A meta-analysis of 7 RCTs found lower liver enzymes, with evidence certainty rated very low to moderate (Jin 2025). Effects on clinical liver outcomes are untested.

Magnitude: Liver fat fell from 11.5% to 9.6% with quercetin versus a 0.1-point fall with placebo (P = 0.013; P is the probability of a difference this large arising by chance) (Li 2024).

Faster Recovery After Muscle-Damaging Exercise ⚠️ Conflicted

A meta-analysis of 13 small placebo-controlled trials, mostly 1,000 mg/day in young men, found less soreness and lower creatine kinase (a muscle-damage marker) after eccentric (muscle-lengthening) exercise, with risk-of-bias concerns in all trials (Rojano-Ortega 2023). The soreness estimate rests on 4 trials with high heterogeneity (inconsistency between trials), and an RCT of 1,000 mg/day found no effect on strength loss, soreness or creatine kinase (O’Fallon 2012). Net: a possible recovery benefit whose size is uncertain.

Magnitude: Soreness SMD (standardized mean difference, effect in standard-deviation units) −1.33 (95% CI −2.57 to −0.09) versus placebo (Rojano-Ortega 2023).

Endurance Capacity ⚠️ Conflicted

Two meta-analyses pooling trials from several groups found statistically significant but trivial gains in VO2max (maximal oxygen uptake, a measure of aerobic fitness) and endurance performance (Kressler 2011; Pelletier 2013). Most single trials were null, and in one analysis gains were confined to untrained people. Net: any gain is too small to matter for trained adults and of uncertain value for untrained ones.

Magnitude: Standardized effect size 0.15 (95% CI 0.02 to 0.27) versus placebo, about a 2% improvement; the 2% figure is the version corrected in the published erratum (Kressler 2011).

Early COVID-19 Outcomes

A meta-analysis of 6 RCTs found fewer hospital and ICU (intensive care unit) admissions, mostly with a lecithin formulation, but no mortality reduction (Cheema 2023). The largest trials were open-label, came from one group, and included co-authors employed by Indena, the formulation’s manufacturer (Di Pierro 2021). No blinded, placebo-controlled trial has confirmed the result.

Magnitude: Hospitalization OR (odds ratio, the relative odds of an event) 0.25 (95% CI 0.10 to 0.62) versus control; all-cause mortality not reduced (Cheema 2023).

Chronic Prostatitis Symptoms ⭕️ Not Central to Health & Longevity

In a double-blind RCT of 30 men with chronic pelvic pain syndrome, 500 mg twice daily for one month improved the NIH-CPSI (National Institutes of Health Chronic Prostatitis Symptom Index, a validated symptom scale) (Shoskes 1999). Proposed mechanisms are anti-inflammatory and mast-cell effects. Replication is limited to the same urologist’s open-label work. The benefit bears on pelvic pain and quality of life, not on aging.

Magnitude: At least 25% symptom improvement in 67% with quercetin versus 20% with placebo; mean scores fell from 21.0 to 13.1 versus 20.2 to 18.8, not compared between groups (Shoskes 1999).

Low 🟩

Fewer Upper Respiratory Infections ⚠️ Conflicted

In 40 trained cyclists, 1,000 mg/day around 3 days of heavy cycling reduced URTI (upper respiratory tract infection) incidence (Nieman 2007). The same group’s 12-week trial in 1,002 adults found no overall effect (Heinz 2010). Net: no reliable protection outside heavy-exertion settings.

Magnitude: URTI in 1 of 20 cyclists on quercetin versus 9 of 20 on placebo (Nieman 2007); no overall difference in 1,002 adults (Heinz 2010).

Glycemic Control and Blood Lipids ⚠️ Conflicted

Meta-analyses find no change in fasting glucose, HbA1c (glycated hemoglobin, 3-month glucose average) or lipids (Ostadmohammadi 2019; Huang 2020), yet one in metabolic syndrome (clustered high blood pressure, sugar, fats) reports lower LDL (low-density lipoprotein) cholesterol (Tabrizi 2020) and an umbrella review lower insulin (Arabi 2023). Net: no dependable benefit.

Magnitude: LDL cholesterol SMD −0.88 (95% CI −1.35 to −0.41) in metabolic syndrome (Tabrizi 2020); no significant change across 17 general trials (Huang 2020).

Lower Coronary Mortality With Flavonol-Rich Diets

In 805 older Dutch men, the highest dietary flavonoid intake, mainly quercetin from tea, onions and apples, was associated with lower coronary death (Hertog 1993); a Danish cohort of 56,048 adults found similar associations for total flavonoids (Bondonno 2019). These observational, whole-food data are indirect for purified supplements.

Magnitude: Coronary death RR (relative risk) 0.42 (95% CI 0.20 to 0.88), highest versus lowest third of intake (Hertog 1993).

Clearance of Senescent Cells (With Dasatinib) ⚠️ Conflicted

Tested only with dasatinib, indirect for quercetin alone. Uncontrolled pilots reported benefits (Justice 2019; Hickson 2019). An open-label bone trial missed its primary endpoint (Farr 2024) and a lung pilot showed no function difference (Nambiar 2023), but a placebo-controlled liver trial improved fibrosis (Koning 2026). Net: unproven for healthy aging.

Magnitude: At least one-stage fibrosis improvement in 47% with dasatinib plus quercetin versus 7% with placebo (Koning 2026); bone-resorption change −4.1% versus −7.7% (P = 0.611) (Farr 2024).

Greater Strength Gains With Training in Older Adults

In 26 older adults, 200 mg/day of quercetin glycosides (sugar-bound forms) during 6 weeks of resistance training increased knee-extension strength more than placebo, without muscle-mass change (Nishikawa 2025). This is one small trial using a glycoside form, indirect for aglycone (sugar-free) supplements.

Magnitude: Maximal force rose to 115.1% of baseline with quercetin versus 105.3% with placebo (Nishikawa 2025).

Speculative 🟨

Lifespan Extension in Animal Models

Quercetin extended roundworm lifespan (Pietsch 2009), and intermittent dasatinib plus quercetin raised remaining survival in old mice (Xu 2018). No human lifespan data exist; the basis is animal only.

Preservation of NAD+ via CD38 Inhibition

Quercetin inhibited CD38 and raised NAD+ in cell studies (Escande 2013). Whether oral doses reach inhibitory tissue levels in humans is unknown; the basis is mechanistic only.

Lower Systemic Inflammation ⚠️ Conflicted

One meta-analysis found lower CRP (C-reactive protein, an inflammation marker) (Mohammadi-Sartang 2017); another found none (Ou 2020). CRP is an unvalidated surrogate here. Net: no consistent signal.

Hormonal Profile in Polycystic Ovary Syndrome ⭕️ Not Central to Health & Longevity

A systematic review of 3 small trials and animal studies reports lower testosterone and insulin resistance (Pourteymour Fard Tabrizi 2020). These are unvalidated hormonal markers; the item bears on reproductive health.

Benefit-Modifying Factors

  • Genetic polymorphisms: quercetin lowered systolic pressure in APOE (apolipoprotein E gene, which encodes a cholesterol-transport protein) ε3/ε3 carriers but not in ε4 carriers, who instead showed lower HDL (high-density lipoprotein) cholesterol (Egert 2010).
  • Baseline blood pressure: blood pressure fell in stage 1 hypertension but not in prehypertension (Edwards 2007); meta-analytic effects were largest at doses of 500 mg/day or more (Serban 2016).
  • Baseline uric acid and senescent-cell burden: uric acid fell from a high-normal baseline (Shi 2016); senolytic bone responses concentrated in women with the highest T-cell p16 (a senescence marker) levels (Farr 2024).
  • Sex: women showed a non-significant trend toward about twice the liver-fat reduction of men (Li 2024), whereas around bypass surgery vascular benefits appeared only in men (Mury 2025).
  • Pre-existing conditions: signals are strongest in hypertension, fatty liver disease and metabolic syndrome; healthy adults with normal blood pressure showed no blood-pressure change (Conquer 1998).
  • Age and fitness: fewer sick days appeared only in physically fit adults aged 40 or older (Heinz 2010); older adults gained extra strength with training (Nishikawa 2025).
  • Formulation: a systematic review found that lecithin phytosome (quercetin bound to phospholipids) and oligoglucoside (quercetin bound to short sugar chains) forms reach roughly 20-fold higher blood levels than plain aglycone, and fat-containing meals roughly double absorption (Liu 2025).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse clinical endpoint has been replicated across controlled trials, and oral trials of up to 1 g/day for 12 weeks report adverse events only qualitatively as rare and mild.

Medium 🟥 🟥

Altered Blood Levels of Co-Administered Drugs

Human pharmacokinetic studies from independent groups show quercetin raising exposure to P-glycoprotein, OATP1B1, CYP2C9, CYP2E1 and CYP1A2 substrates (Kim 2009; Wu 2012; Bedada 2018; Bedada 2018; Xiao 2014) and lowering exposure to the sedative midazolam, a CYP3A substrate (Duan 2012). Clinical harm is documented only in a case report of a raised INR (international normalized ratio, a clotting-time measure) on warfarin (Patel 2022). Narrow-therapeutic-index drugs (where small level changes matter) carry the most risk.

Magnitude: Fexofenadine AUC (area under the concentration–time curve, total drug exposure) 55% higher after 7 days of 500 mg three times daily versus the placebo phase (3,098.6 versus 2,005.3 ng·h/mL) (Kim 2009).

Low 🟥

Mild Gastrointestinal Discomfort and Other Minor Effects ⚠️ Conflicted

A safety review found adverse effects in human trials rare and mild (Andres 2018), and ConsumerLab notes gastrointestinal discomfort that taking quercetin with food reduces (ConsumerLab review). A 12-week RCT of 500 mg/day found no intervention-related adverse events (Li 2024). Net: uncommon, mild and not clearly above placebo.

Magnitude: Not quantified in available studies. Trials report adverse events qualitatively without rates for each group (Andres 2018).

Kidney Injury at High Exposure ⚠️ Conflicted

Intravenous quercetin caused dose-limiting kidney toxicity in cancer patients (Ferry 1996), a route and exposure gap from oral supplements. A meta-analysis of oral RCTs found no kidney-function change (Jin 2025). Net: no renal signal at oral doses up to 1 g/day.

Magnitude: 3 of 14 patients given 945 mg/m² intravenously had clinically significant renal toxicity; no control group (Ferry 1996).

Adverse Events of Senolytic Regimens (With Dasatinib)

Tested only with dasatinib, which drives most toxicity. In a placebo-controlled liver trial, adverse events were more frequent with the combination but self-limiting (Koning 2026); a lung-fibrosis trial reported excess sleep disturbance and anxiety (Nambiar 2023).

Magnitude: Adverse events in 82% with dasatinib plus quercetin versus 43% with placebo (Koning 2026); sleep disturbance or anxiety in 4 of 6 versus 0 of 6 (Nambiar 2023).

Speculative 🟨

Tumor Promotion in Rodent Models

High-dose feeding caused mostly benign kidney tumors in male rats (Dunnick 1992) and accelerated estrogen-induced breast tumors in rats (Singh 2010). No human data exist; the basis is animal only.

Bleeding Tendency ⚠️ Conflicted

Single doses inhibited platelet aggregation in volunteers (Hubbard 2004); 1 g/day for 28 days did not, versus placebo (Conquer 1998). No bleeding events are reported. Net: an inconsistent laboratory signal only.

Reduced Thyroid Function

Quercetin suppressed thyroid hormone synthesis genes and iodide uptake in rats (Giuliani 2014). No human thyroid data exist; the basis is animal only.

Reduced Iron Absorption

Quercetin lowered intestinal non-heme iron (the form in plant foods and supplements) absorption in rodents (Lesjak 2014). Human iron-status effects of supplements are unstudied; the basis is animal and cell data.

Headache With Alcohol

A circulating quercetin metabolite inhibited ALDH2 (aldehyde dehydrogenase 2, the enzyme clearing acetaldehyde) in vitro, a proposed cause of red-wine headaches (Devi 2023). The basis is mechanistic only.

Demyelination (With Dasatinib)

Dasatinib plus quercetin caused demyelination (loss of nerve-fiber insulation) in young and aged mice without cell death (Lombardo 2026). Tested only as the combination; no human data exist.

Risk-Modifying Factors

  • Genetic polymorphisms: CYP3A5 (a drug-metabolizing enzyme) expressers showed stronger midazolam-exposure falls (Duan 2012), and ABCB1 (the P-glycoprotein gene) 3435 TT carriers stronger falls for talinolol, a beta-blocker (a heart-rate- and blood-pressure-lowering drug) (Wang 2013); APOE ε4 carriers saw HDL decrease (Egert 2010).
  • Baseline biomarkers: reduced kidney function (low eGFR, estimated glomerular filtration rate) heightens concern given kidney toxicity with intravenous dosing and animal data in pre-damaged kidneys summarized in a safety review (Andres 2018); an INR already at the upper therapeutic limit leaves no margin for interaction.
  • Sex: in women undergoing bypass surgery, quercetin increased inflammatory protein signatures rather than reducing them (Mury 2025); estrogen-dependent tumor promotion in rats concerns women with hormone-sensitive cancers (Singh 2010).
  • Pre-existing conditions: chronic kidney disease, estrogen-dependent cancers and conditions treated with interacting drugs, such as atrial fibrillation (an irregular heart rhythm) treated with anticoagulants (drugs that slow blood clotting), are the main risk modifiers named in a safety review (Andres 2018).
  • Age: older adults take more interacting medications and have lower kidney reserve, which increases exposure to pharmacokinetic interactions; senolytic trials in people over 50 reported more adverse events than placebo (Nambiar 2023).
  • Dose and route: risk rises with intravenous dosing and with high oral exposure from enhanced-absorption forms; a safety review found long-term data above 12 weeks at 1,000 mg/day or more missing (Andres 2018).

Key Interactions & Contraindications

Documented interactions:

  • P-glycoprotein substrates (fexofenadine, an over-the-counter antihistamine): exposure rose 55% (Kim 2009), raising the chance of dose-related effects; talinolol exposure instead fell (Wang 2013). Mitigation: dose separation by several hours.
  • Statins (cholesterol-lowering drugs) carried by OATP1B1 (pravastatin): exposure rose 24% (Wu 2012), raising the risk of statin muscle symptoms. Mitigation: creatine kinase testing if new muscle pain appears.
  • CYP2C9 substrates (diclofenac, an over-the-counter anti-inflammatory; also celecoxib): diclofenac exposure rose after 10 days of 500 mg twice daily (Bedada 2018), increasing gastrointestinal and kidney side-effect risk. Mitigation: lowest effective analgesic dose.
  • Warfarin (an anticoagulant, a drug that slows blood clotting): a case report described a raised INR that normalized after quercetin was stopped (Patel 2022), indicating bleeding risk. Mitigation: INR check within one week of starting or stopping quercetin.
  • CYP3A substrates (midazolam; by extension nirmatrelvir in Paxlovid, tacrolimus): midazolam exposure fell with 13 days of 500 mg/day (Duan 2012), with a non-significant trend at 1,500 mg/day (Nguyen 2015), risking reduced drug effect. Mitigation: pausing quercetin during such therapy.
  • CYP2E1 and CYP1A2 substrates (chlorzoxazone, a muscle relaxant; caffeine; theophylline, an asthma drug): chlorzoxazone exposure rose 69% (Bedada 2018) and caffeine metabolism slowed (Xiao 2014), risking sedation or restlessness. Mitigation: lower caffeine intake; theophylline levels.
  • Cyclosporine (an immunosuppressant with a narrow therapeutic index, P-glycoprotein and CYP3A substrate): a controlled human pharmacokinetic study tested quercetin with oral cyclosporine (Choi 2004); shifted levels risk rejection or kidney toxicity. Mitigation: cyclosporine level checks after starting or stopping quercetin.
  • Cefprozil (an oral antibiotic): no interaction found; 500 mg/day of quercetin did not change cefprozil levels (Jia 2016).
  • Saquinavir (an HIV (human immunodeficiency virus) antiviral; P-glycoprotein and CYP3A substrate): no interaction found; 500 mg three times daily did not change plasma saquinavir levels (DiCenzo 2006).
  • Rosiglitazone (a diabetes drug; CYP2C8 substrate, a drug-metabolizing liver enzyme): no interaction found; 3 weeks of quercetin did not change rosiglitazone exposure (Kim 2005).
  • Nifedipine (a blood-pressure drug that relaxes blood vessels; CYP3A substrate): no interaction found; a single 400 mg quercetin dose did not change nifedipine exposure (Rashid 1993).
  • Resveratrol (a grape-derived polyphenol supplement): no interaction found; 500 mg of quercetin twice daily did not change steady-state trans-resveratrol exposure (la Porte 2010).
  • Antiplatelet drugs (which reduce platelet clumping) and anticoagulants (aspirin, ticlopidine, clopidogrel, warfarin, dabigatran): no interaction found; in a study run by the manufacturer Indena, Quercetin Phytosome did not change bleeding time or INR (Riva 2019).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Antihypertensive drugs (blood-pressure-lowering medications such as amlodipine, lisinopril, losartan): inferred from additive blood-pressure lowering; possible dizziness or low blood pressure. Mitigation: home blood-pressure tracking during the first 4 weeks.
  • Digoxin (a narrow-therapeutic-index heart drug and P-glycoprotein substrate): inferred from quercetin’s P-glycoprotein effects; no human digoxin study exists; levels could rise, risking digoxin toxicity. Mitigation: digoxin-level measurement after starting or stopping quercetin.
  • Chemotherapy drugs that act through oxidative damage (e.g., doxorubicin, cisplatin): inferred from antioxidant activity that may interfere with certain chemotherapy drugs, a caution raised by Memorial Sloan Kettering Cancer Center, a hospital that itself delivers chemotherapy (MSKCC About Herbs). Mitigation: coordination with the treating oncologist.
  • Dasatinib in senolytic stacks: inferred from dasatinib’s CYP3A4 metabolism (SPRYCEL label) and quercetin’s CYP3A effects; dasatinib exposure could change, risking more dose-related side effects or reduced effect. Mitigation: trial-tested intermittent schedules only.
  • Blood-pressure-lowering supplements (fish oil, garlic, magnesium): inferred from additive blood-pressure lowering; possible dizziness or low blood pressure. Mitigation: introducing one at a time while tracking blood pressure.
  • Antiplatelet supplements (fish oil, ginkgo, vitamin E): inferred from additive platelet inhibition; bleeding risk. Mitigation: no stacking before procedures.
  • Iron supplements: inferred from reduced iron absorption in rodents; lower iron uptake. Mitigation: iron taken at least 2 hours apart from quercetin.
  • Alcohol: inferred from in-vitro ALDH2 inhibition by a quercetin metabolite; possible headache and flushing. Mitigation: dosing away from alcohol intake.

Populations who should avoid Quercetin:

  • Pregnancy and breastfeeding: inferred from quercetin’s inhibition of cell-signaling enzymes such as PI3K, with no human safety data for supplemental doses, per a safety review (Andres 2018); no human data.
  • Chronic kidney disease: inferred from kidney toxicity with intravenous dosing (Ferry 1996) and animal data showing worsened injury in pre-damaged kidneys, as summarized in a safety review (Andres 2018); no oral human data.
  • Estrogen-dependent cancers (e.g., hormone-receptor-positive breast cancer): inferred from accelerated estrogen-induced tumors in rats (Singh 2010); no human data.
  • People receiving chemotherapy: inferred from antioxidant activity that may interfere with certain chemotherapy drugs, a concern raised by the Memorial Sloan Kettering monograph, from a cancer hospital that delivers chemotherapy (MSKCC About Herbs); no human data.
  • People on warfarin or narrow-therapeutic-index transporter substrates (e.g., digoxin, cyclosporine) without monitoring: based on the warfarin case report (Patel 2022) and human pharmacokinetic studies (Kim 2009).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Medication review before starting: screening all prescription and over-the-counter drugs against P-glycoprotein, OATP1B1 and CYP substrate lists prevents the exposure changes documented in human studies (Kim 2009).
  • INR check on warfarin: an INR test 3–7 days after starting or stopping quercetin catches the raised clotting time and bleeding risk reported in a case (Patel 2022).
  • Oral dose ceiling: keeping to 500–1,000 mg/day, the range a safety review reports as tested for up to 12 weeks, avoids untested long-term high exposure and the kidney signal seen with intravenous dosing (Andres 2018).
  • Kidney threshold: creatinine at baseline and 8–12 weeks, with use stopped if eGFR falls more than 25% from baseline, guards against kidney injury.
  • Dosing with food: taking doses with a meal, and splitting 1,000 mg into two 500 mg doses, reduces gastrointestinal discomfort (ConsumerLab review).
  • Iron separation: iron supplements or iron-rich meals at least 2 hours apart limit the reduced iron absorption seen in rodents (Lesjak 2014).
  • Pre-procedure pause: stopping about 7 days before surgery or dental extraction limits bleeding risk from platelet inhibition (Hubbard 2004).
  • Blood-pressure tracking with antihypertensives: home readings several times weekly for 4 weeks detect additive lowering and dizziness.
  • Supervised senolytic courses: dasatinib combinations only on trial-tested intermittent schedules with prescriber oversight limit the excess adverse events, sleep disturbance and anxiety seen in trials (Koning 2026; Nambiar 2023).

Therapeutic Protocol

Doses below are cited to trials or named practitioners; other parameters without a citation (timing, cycling, titration steps) reflect common practice.

  • Daily cardiometabolic dose: 500 mg/day (Shi 2016; Li 2024) to 730 mg/day (Edwards 2007); ConsumerLab cites 500 mg once or twice daily as typical (ConsumerLab review).
  • Exercise and immune dose: 1,000 mg/day for 3 weeks around heavy training (Nieman 2007) or 12 weeks (Heinz 2010), an approach popularized by David Nieman’s Appalachian State University group.
  • Phytosome dose: 1,000 mg/day of Quercetin Phytosome (Di Pierro 2021), chosen because lecithin delivery raised blood levels up to 20-fold in a study by the manufacturer, Indena (Riva 2019).
  • Intermittent senolytic dose: dasatinib 100 mg plus quercetin 1,000–1,250 mg on 2–3 consecutive days, given weekly for 3 weeks (Justice 2019) or every 28 days (Farr 2024), developed by James Kirkland and Tamara Tchkonia at Mayo Clinic.
  • Competing approaches: continuous daily dosing targets blood pressure and metabolic markers; intermittent “hit-and-run” dosing targets senescent cells, which re-accumulate slowly (Hickson 2019). Neither has outcome data in healthy adults.
  • Time of day: with a fat-containing meal, which roughly doubles absorption in a systematic review (Liu 2025); morning dosing during senolytic courses, given reported sleep disturbance (Nambiar 2023).
  • Half-life: about 11 hours after oral glycosides (Graefe 2001); the combined elimination half-lives under 11 hours underpin intermittent senolytic dosing (Hickson 2019).
  • Single versus split dosing: the 11-hour half-life permits once-daily dosing; 1,000 mg/day is commonly split into two 500 mg doses, as in trials (Shoskes 1999; Mury 2025).
  • Genetic factors: APOE ε4 carriers showed no blood-pressure benefit (Egert 2010); CYP3A5 and ABCB1 genotypes modified interaction strength (Duan 2012; Wang 2013).
  • Sex differences: women showed a non-significant trend toward larger liver-fat reductions (Li 2024); men alone showed vascular benefits around bypass surgery (Mury 2025). No sex-specific doses exist.
  • Age: older adults gained extra strength at 200 mg/day of glycosides with training (Nishikawa 2025); higher medication burden in older age favors the lower end of dosing.
  • Baseline biomarkers: benefits concentrated in elevated blood pressure (Edwards 2007), high-normal uric acid (Shi 2016) and high senescent-cell burden (Farr 2024).
  • Pre-existing conditions: hypertension, fatty liver disease and metabolic syndrome carry the trial signals; kidney disease and interacting drugs are the main safety qualifiers in a safety review (Andres 2018).

Discontinuation & Cycling

  • Lifelong or short-term: a safety review found adequate safety data lacking for use beyond 12 weeks at 1,000 mg/day or more (Andres 2018); open-ended use rests on extrapolation.
  • Withdrawal effects: none reported; blood-pressure and uric-acid effects are expected to fade within days to weeks, consistent with the 11-hour half-life (Graefe 2001).
  • Tapering: not needed; no rebound effect has been described for oral quercetin.
  • Cycling for daily use: no evidence shows that cycling preserves effect; continuous use is the tested pattern for blood pressure and liver fat.
  • Intermittent senolytic schedules: senolytic protocols are inherently cyclic, with 2–3 dosing days every 2 weeks (NCT04685590) to every 4 weeks (Farr 2024); when stopping, dasatinib and quercetin are stopped together.
  • Temporary pauses: practitioners commonly pause about a week before surgery and when starting narrow-therapeutic-index drugs, given platelet and transporter effects.

Sourcing and Quality

  • Forms: quercetin dihydrate (about 90% quercetin), anhydrous aglycone, rutin (49.5% quercetin) (ConsumerLab review), isoquercitrin and lecithin phytosome; blood levels differ up to roughly 20-fold across forms in a systematic review (Liu 2025).
  • Label accuracy: ConsumerLab, which also sells a paid certification program to manufacturers, found one rutin product with 17.4% of its labeled amount (ConsumerLab review).
  • Third-party testing: USP (United States Pharmacopeia), NSF (NSF International) or ConsumerLab certification verifies identity, quantity and freedom from contaminants such as heavy metals and solvent residues.
  • Reputable brands: Thorne supplied quercetin for the SToMP-AD trial (NCT04685590); Life Extension Bio-Quercetin and Indena’s Quercefit phytosome are widely used enhanced-absorption products.
  • Co-formulations: products often add vitamin C or bromelain; no trial shows these additions improve outcomes, and they complicate dose accounting.
  • Senolytic sourcing: dasatinib is a prescription leukemia drug (SPRYCEL label); senolytic trials used either standard quercetin, such as Thorne capsules in SToMP-AD (NCT04685590), or Quercetin Phytosome (NCT04313634; NCT06018467).

Practical Considerations

  • Time to effect: blood pressure and uric acid changed within 2–4 weeks (Edwards 2007; Shi 2016); liver fat after 12 weeks (Li 2024); senescent-cell markers 11 days after a 3-day course (Hickson 2019).
  • Common pitfalls: equating quercetin alone with the dasatinib combination; under-dosing with rutin products; assuming antioxidant effects in the body; and overlooking interactions with common drugs.
  • Formulation pitfall: enhanced-absorption forms raise blood levels many-fold in a systematic review, so milligram doses are not interchangeable with trials that used plain quercetin (Liu 2025).
  • Regulatory status, United States: marketed as a dietary supplement; the FDA raised no questions about GRAS food use at up to 500 mg per serving (FDA GRN 341).
  • Regulatory status, European Union: EFSA (European Food Safety Authority) did not establish a cause-and-effect relationship for any of four proposed quercetin health claims (EFSA opinion).
  • Funding and conflicts: much evidence comes from parties with financial stakes: Mayo Clinic, which holds senolytic patents (Mayo Clinic news release), Indena for phytosome trials (Riva 2019), and Quercegen Pharma, the GRAS notifier (FDA GRN 341).
  • Cost and access: quercetin is inexpensive and widely available; dasatinib is approved only for certain leukemias (SPRYCEL label), so senolytic use is off-label and requires a prescriber.

Interaction with Foundational Habits

  • Sleep: no direct effect shown for quercetin alone; a phytosome trial in chronic fatigue reported better sleep scores (Rondanelli 2023; Indena co-authors), while the dasatinib combination increased sleep disturbance (Nambiar 2023). Direction: none to mildly potentiating alone; disruptive with dasatinib; morning dosing avoids overlap.
  • Nutrition: potentiating with fat-containing meals, which roughly double absorption per a systematic review (Liu 2025); onions, capers, apples, kale and tea supply quercetin, though typical diets provide only tens of milligrams of flavonoids daily (Hertog 1993). Possible blunting of iron absorption (Lesjak 2014) favors separating doses from iron-rich meals.
  • Exercise: mildly potentiating: meta-analyses show trivial endurance gains (Kressler 2011) and possibly faster recovery (Rojano-Ortega 2023) and added strength gains in older adults (Nishikawa 2025). No human study shows blunted training adaptations; timing relative to workouts has not been tested.
  • Stress management: no direct interaction known; no human study has measured cortisol or stress responses with quercetin. The dasatinib combination increased anxiety reports in one trial (Nambiar 2023), an indirect consideration during senolytic courses.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes reference points for markers quercetin may change and for safety. It includes seated blood pressure averaged over several days, serum uric acid, serum creatinine with eGFR, and ALT (alanine aminotransferase, a liver enzyme); a baseline INR is added for anyone taking warfarin, and all current medications are listed for interaction screening.

Ongoing monitoring follows this cadence: home blood pressure weekly for the first 4 weeks, then monthly; uric acid, creatinine and ALT at 8–12 weeks, then every 6–12 months; and INR 3–7 days after starting or stopping quercetin while on warfarin. Senolytic courses with dasatinib add the monitoring set by the prescriber for that drug. Success means a sustained systolic reduction or lower uric acid without rising creatinine or ALT and without new side effects.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure <120/<80 mmHg (ACC/AHA 2017 guideline) Expected to change: primary benefit marker ACC/AHA (American College of Cardiology/American Heart Association) guideline (ACC/AHA 2017 guideline); its members diagnose and treat hypertension, so thresholds shape their patient base. Conventional normal range is the same <120/<80 mmHg. Seated morning readings before dosing, averaged over 2 or more, give the most stable values.
Serum uric acid 3.5–7.2 mg/dL men, 2.6–6.0 mg/dL women (standard reference range) Expected to change: fell about 26 µmol/L in a trial Benefit evidence from Shi 2016. Alcohol or intense exercise beforehand can raise values; a morning fasting sample is preferred.
Serum creatinine with eGFR 0.7–1.3 mg/dL men, 0.6–1.1 mg/dL women (standard reference range) Safety check: a sustained rise stops use Kidney toxicity seen with intravenous dosing (Ferry 1996). Heavy exercise or high meat intake in the prior 24 hours can raise values; urine albumin-to-creatinine ratio is the usual pairing in kidney disease.
ALT ≤29–33 U/L men, ≤19–25 U/L women (ACG upper limit of healthy normal) Safety check; also expected to fall in fatty liver ACG (American College of Gastroenterology) guideline (ACG 2017 guideline); its members evaluate liver disease, so lower cutoffs widen referrals. Conventional reference range about 7–55 U/L. Fall in fatty liver per Jin 2025.
INR (only if on warfarin) No established target for quercetin; track change from the individual’s own baseline within the prescriber’s range Safety check: a rise signals an interaction Standard reference range 0.8–1.2 without anticoagulation. Interaction case: Patel 2022. Testing falls 3–7 days after starting or stopping.

Qualitative markers:

  • Stomach comfort and headache frequency
  • Sleep quality, especially during senolytic courses
  • Muscle soreness and recovery after hard training
  • Frequency and duration of upper respiratory infections
  • Energy and fatigue levels
  • Unusual bruising or bleeding

Emerging Research

  • SToMP-AD phase 2: NCT04685590 randomizes 48 people with early Alzheimer’s disease to dasatinib plus quercetin or placebo; primary endpoint safety; active, completion 2029. Positive: supports blinded efficacy trials; null or harmful: weakens the brain-aging case for the combination.
  • Adipose senescence in older adults: NCT05653258, phase 2/3, 160 participants, tests dasatinib plus quercetin on insulin sensitivity and glucose tolerance; recruiting, completion 2028. Positive: a first metabolic benefit of the combination in older adults; null: keeps the senolytic benefit at Low.
  • Quercetin phytosome and biological age: NCT07760506, 60 participants, compares 500 mg/day of a commercial phytosome with placebo on an inflammation clock and Phenotypic Age; recruiting, completion 2028. Positive: first quercetin-alone aging-biomarker signal; null: supports the conclusion that daily quercetin does little for aging biology.
  • Quercetin alone in lung fibrosis: NCT07466420, 100 participants, measures telomere length, lung function and senescence factors; recruiting, completion 2029. Positive: shows senolytic-type benefit without dasatinib; null: confirms quercetin needs a partner drug.
  • SEN-SURVIVORS: NCT04733534, phase 2, 120 adult childhood-cancer survivors, compares dasatinib plus quercetin with fisetin on walking speed and p16; active, completion 2027. Positive: functional benefit in accelerated aging; null: weakens the frailty case.
  • SENIOR osteoporosis trial: NCT06018467 compared dasatinib plus quercetin, nicotinamide riboside and control on bone resorption in 120 participants; completed April 2026, no results posted. Positive results would revive the bone case after the null primary endpoint in Farr 2024; null results would close it.
  • Patient selection by senescent burden: exploratory responses concentrated in high-p16 women (Farr 2024); trials stratified by senescence biomarkers could strengthen the case for selected adults or show no subgroup benefit.
  • Sex-specific responses: quercetin helped men’s vessels but increased inflammatory signatures in women (Mury 2025); replication could reveal a sex-specific risk that weakens the case for women.
  • Central nervous system safety: demyelination in mice given dasatinib plus quercetin (Lombardo 2026) calls for brain-imaging safety endpoints in human trials, which could weaken the senolytic case.
  • Long-term safety and formulation: a safety review found no data beyond 12 weeks at 1,000 mg/day (Andres 2018), and a systematic review found enhanced-absorption forms raise exposure many-fold (Liu 2025); long-term trials of these forms could confirm safety or reveal new risks.

Conclusion

Quercetin is a common plant compound sold as an inexpensive supplement and studied both alone and paired with a prescription cancer drug to clear worn-out cells linked to aging. For health-focused adults, the most consistent finding is a small drop in blood pressure, mainly in people whose pressure is already raised. Lower uric acid, less liver fat, faster muscle recovery and better outcomes in early viral illness rest on smaller or weaker studies, and claims for blood sugar, cholesterol and inflammation do not hold up.

The aging-focused use with the cancer drug remains unproven. Early uncontrolled studies looked promising, but a bone trial with an untreated comparison group missed its main goal, a small lung study showed no clear gain, one liver trial was an exception, and the pairing brings more side effects. Animal lifespan gains have not been shown in people.

Taken alone at usual doses for up to three months, quercetin appears well tolerated. Its main risk is changing how the body handles common drugs, including a drug that slows blood clotting, a cholesterol drug and an allergy medicine; long-term safety of high doses and enhanced-absorption forms is unknown.

The evidence base is broad but thin: many small, short trials, few measuring illness or death, and important parts produced by parties with a financial stake, including the institution holding patents on the drug pairing and the maker of an enhanced-absorption form. Quercetin offers modest, uncertain benefits and manageable risks rather than a proven route to longer life.

Top - Benefits - Risks - Protocol